UPDF AI

Nanoparticle‐Based Tetracycline Delivery Systems: Advancing Therapeutic Effectiveness and Tackling Antibiotic Resistance

Mahsa Molaei Nasr,Mehrab Pourmadadi,3 Authors,M. A. Aboudzadeh

2025 · DOI: 10.1002/ppsc.202500036
4 Citations

TLDR

Polymer‐based TCN drug delivery strategies designed to combat antibiotic resistance effectively are explored and Scalability, biocompatibility, and safety challenges in in vitro to in vivo transitions are highlighted, emphasizing the need for efficient drug delivery research and TCN's role in addressing global health challenges.

Abstract

Although antibiotics such as tetracycline (TCN) are widely used to treat bacterial infections, their misuse has resulted in the development of antibiotic resistance, which has decreased the efficacy of common use of these medications and complicated their application in healthcare. As a result, novel techniques are needed to reduce TCN antibiotic resistance. Integrating TCN with cutting‐edge nanomaterials, such as lipid, polymer, carbon, and inorganic nanoparticles, as well as targeted and controlled drug delivery, is one efficient way to address this issue. In certain situations, this allows for precise drug release at the infection sites using stimuli–responsive drug delivery systems, such as pH changes, enzymes, and reactive oxygen species. Moreover, TCN co‐delivery with other therapeutic agents can help address public health concerns like cancer and inflammatory illnesses, combat bacterial resistance, and enhance tissue regeneration. These innovations have greatly enhanced TCN solubility, stability, and targeted delivery while lowering systemic side effects and the possibility of generating resistant bacterial strains. Here polymer‐based TCN drug delivery strategies designed to combat antibiotic resistance effectively are explored. Scalability, biocompatibility, and safety challenges in in vitro to in vivo transitions are highlighted, emphasizing the need for efficient drug delivery research and TCN's role in addressing global health challenges.